AtriCure, Inc. (ATRC) — 分析摘要
AtriCure, Inc.(ATRC)的市值为1.76十亿美元,最近一年的营收同比增长了+14.9%。净利润率为-2.1%。当前市盈率为-383.7倍。
核心要点
- 营收同比变化+14.9%
- 净利润率-2.1%
- 市盈率-383.7倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,ATRC的营收增长为+14.9%,市盈率为-383.7倍。
AtriCure, Inc. (ATRC)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 6.7x — 高杠杆,存在再融资风险
利息保障倍数为 -0.5x — 盈利不足以覆盖利息支出
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
1,350
总部
MASON, OH
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。